Navigation Links
Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
Date:9/25/2013

Irvine, CA (PRWEB) September 25, 2013

Proove Biosciences Inc. (http://www.proovebio.com), the leading personalized pain medicine laboratory, announces that they will again be presenting research on the genetics of pain medicine at a major scientific meeting this year. This weekend, Proove will present preliminary findings from a clinical study during the poster session and will exhibit at the American Academy of Pain Management’s 24th Annual Clinical Meeting at the JW Marriott Orlando, Orlando, Florida. The event will be held from September 26th to September 29nd. Proove will be presenting research on the clinical and economic outcomes of using the Proove Narcotic Risk Genetics Test in the treatment and management of pain.

The American Academy of Pain Management is the one of largest pain management organizations in the nation and uniquely embraces an integrative model of care, which includes bringing together all appropriate therapeutic approaches and a team of clinicians to reduce pain and achieve optimal health and healing. The AAPM also offers continuing education, publications, and advocacy.

Proove Biosciences CEO, Brian Meshkin, states, “We are pleased to again have our research selected by experts in the field to be presented at another industry leading conference. The AAPM’s Annual Clinical Meeting brings together over 1200 clinicians across all disciplines in pain management, and offers Proove another opportunity to help educate about the importance of using genetic testing in pain management.”

Proove will be exhibiting at the scientific meeting to help educate clinicians about its proprietary genetic testing to personalize pain medicine and will be presenting some additional preliminary data at the poster session on the R.A.C.E.R. Study,”Retrospective Analysis of the Clinical and Economic Results (R.A.C.E.R.) of Genotyping Chronic Pain Patients to Guide Medical Detoxification of Prescription Opioid Analgesic Abuse (RxO): Two-Year Study.” In this study, principal investigator, Dr. Gregory Smith, utilized an integrated, team-based medical approach to detoxification. In the R.A.C.E.R. Study, Proove investigators conducted a pilot study to explore how genotyping could correlate or associate with outcomes of medical detoxification, and whether genotype could predict outcomes. At this meeting, researchers will prevent preliminary findings that suggest the Proove Narcotic Risk test may assist clinicians in improving outcomes of medical detoxification in patients abusing prescription narcotic pain medication.

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at http://www.prweb.com/releases/2013/9/prweb11160656.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
2. Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
3. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
4. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
5. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
6. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
7. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
8. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
9. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
10. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
11. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... ... June 16, 2017 , ... Cognition Corporation , ... two more sessions of its “From the Helm” Webinar Series. , The ... online templates for design control exercises. Led by David Cronin, Cognition’s CEO, the ...
(Date:6/15/2017)... ... 15, 2017 , ... Cybrexa Therapeutics, a start-up cancer therapeutics ... in the amount of $6 million. An investment vehicle affiliated with HighCape Partners, ... The Series B funding will enable Cybrexa to complete the build-out of its ...
(Date:6/15/2017)... ... 15, 2017 , ... Adam Equipment, a leading provider of ... lab workstation. The guide outlines the procedure in four simple steps, using comprehensive ... anti-vibration table, OIML/ASTM certified weights, and Adam DU specialized software. , A lab ...
(Date:6/14/2017)... USA – , ... ... June 14, 2017 -- Diagenode, a leading global provider ... has licensed a new technology specific for ChIP-sequencing from ... immunoprecipitation followed by sequencing (ChIP-seq) allows the study of ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):